Navigation Links
GW Pharmaceuticals Commences Phase 1 Clinical Trial of GWP42006 as a Potential Treatment for Epilepsy
Date:9/17/2013

LONDON, Sept. 18, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.  

Over the last five years, GW has conducted an extensive pre-clinical cannabinoid research program in the field of epilepsy in collaboration with the University of Reading in the United Kingdom. This research has led to the emergence of a number of promising cannabinoid therapeutic candidates showing anti-epileptic effects. GWP42006, one of the most promising of those candidates, is a non-psychoactive cannabinoid extracted from specific chemotypes of the cannabis plant which has shown the ability to treat seizures in pre-clinical models of epilepsy with significantly fewer side effects than currently approved anti-epileptic drugs1.

"We are pleased to have advanced GWP42006 to first dose in man, a significant milestone in the development of this novel product candidate. The decision to progress into Phase 1 follows several years of highly promising pre-clinical research," stated Dr. Stephen Wright, Director of Research and Development at GW. "We believe that GWP42006 has the potential to become an important advance in the treatment of epilepsy, a condition for which there remains a substantial unmet medical need."

Dr. Ben Whalley, Senior Lecturer in Pharmacology at the Reading School of Pharmacy, said, "Our research collaboration with GW over the last several years has shown that GWP42006 not only exerts significant anticonvulsant effects in a wide range of preclinical models of seizure and epilepsy but is also better tolerated compared to existing anti-epileptic drugs. It is also noteworthy that GWP42006 appears to employ a different mechanism of action to currently available anti-epileptic
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Teva Pharmaceuticals Donates to the National Multiple Sclerosis Society in recognition of Jack Osbourne as He Competes on "Dancing with the Stars"
2. JHP Pharmaceuticals Enters Agreement to Produce Unique Late Stage Ophthalmic Product
3. Actinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
4. Frost & Sullivan Lauds Adcock Ingrams Capability to Innovatively Cater to the Dynamic Needs of Emerging Pharmaceuticals Markets
5. Dr. David Hangauer, Chief Scientific Officer and Co-Founder, commits his career to Kinex Pharmaceuticals
6. Access Pharmaceuticals Awarded Second European Patent for MuGard
7. Cardioxyl Pharmaceuticals Appoints Shi Yin Foo, M.D., Ph.D., As Chief Medical Officer
8. Caldera Pharmaceuticals Announces Closing of Financing
9. HedgePath Pharmaceuticals Enters into Key Collaboration with Mayne Pharma
10. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
11. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ("Neurelis") ... to end the option held by Biotie to purchase ... development of NRL-1 (intranasal diazepam) for pediatric and adult ... Over the past year, Biotie has advanced the development ... for the pivotal clinical work required for NDA submission ...
(Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
(Date:7/10/2014)... Calif. , July 10, 2014  Breg, ... and services, has launched the FreeRunner™ knee brace ... who suffer from patella mal-tracking return to active ... differently than other braces, providing support when patients ... normally when they don,t. Patellofemoral issues ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... 14, 2012  The Consumer Healthcare Products Association (CHPA) ... into law House Bill 2263—anti-meth legislation authored by ... 23rd state to adopt real-time, stop-sale technology known ... The proven system—in a process similar ...
... SCHLIEREN-ZURICH, Switzerland, May 14, 2012 The ALS ... it has entered into collaboration with Neurotune ... Neuron or Lou Gehrig,s disease). (Photo: ... "Maintaining the health of motor neurons ...
Cached Medicine Technology:CHPA Applauds Arizona's Adoption Of HB 2263 2The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease 2The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease 3
(Date:7/13/2014)... According to a new market research ... Component (processor, GPU, DSP, connectivity), Technology Node (45nm-5nm), ... - Forecast and Analysis to 2014-2020", published by ... Market is expected to reach $61.70 Billion by ... 2014 to 2020. , Browse 71 market data ...
(Date:7/13/2014)... Serena Gordon HealthDay ... A new type of sensor for people with diabetes ... using saliva instead of blood, researchers report. Scientists at ... tested it using artificial saliva. It uses light, metal and ... sugar. "Everybody knows that diabetics have to prick their ...
(Date:7/13/2014)... 13, 2014 The federal court overseeing ... filed against Johnson & Johnson’s Ethicon, Inc. is ... is expected to get underway next month. According to ... District Court, Southern District of West Virginia on July ... August 7, 2014 at 3:00 p.m. July selection is ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular ... has released its new range of elegant Quinceanera ... available at discounted prices. Worldwide clients can enjoy this ... the company’s online shop, there are plenty of beautiful ... with great materials. MyDressCity.com’s hot items are prom gowns, ...
(Date:7/13/2014)... A noninvasive optical imaging device developed at ... later occur in the brain and are a ... results from investigators conducting a clinical trial in ... July 15 in an oral presentation at the ... They also were invited by conference organizers to ...
Breaking Medicine News(10 mins):Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3
... Scientists at Duke University Medical Center may have solved the ... they say may renew interest in gold salts as a ... first used injections of gold salts in the early 1900s ... But treatment came at a high cost: The shots ...
... 22 With health,facilities across the country struggling ... Veterans Affairs (VA) are demonstrating leadership by,collaborating in ... the federal healthcare supply chain. Through the innovative ... and expanding their ongoing,initiatives to both standardize and ...
... of virus in the blood of an HIV-infected personhas ... quickly someone infected with HIV infection progresses to AIDS. ... work that suggests that several other factors in addition ... , Researchers led by Sunil Ahuja, M.D., of the ...
... , , MONDAY, Oct. 22 (HealthDay News) -- If you,re sneaking ... a common device can determine whether someone is a smoker. ... to ferret out people who hide a cigarette habit, ... patients what smoking is doing to their bodies, he added. ...
... vascular surgery, picks up size 7 crochet hooks from a fabric ... in a new technique he has developed to treat varicose veins. ... procedure, called light-assisted stab phlebectomy, or LASP, appear in a study ... , More than 250 patients at UCLA have ...
... Information,Systems (Nasdaq: MEDW ) announced today that ... licensed Mediware,s HCLL(TM) Transfusion,Management software system, which provides ... transfusion errors, improve patient,safety and maximize operational efficiency. ... is based in Dallas, Texas, and,through its subsidiaries, ...
Cached Medicine News:Health News:Scientists discover how gold eases pain of arthritis 2Health News:DoD and VA to Reduce Healthcare Supply Chain Costs 2Health News:DoD and VA to Reduce Healthcare Supply Chain Costs 3Health News:DoD and VA to Reduce Healthcare Supply Chain Costs 4Health News:Blood Test Catches Secret Smokers 2Health News:Blood Test Catches Secret Smokers 3Health News:UCLA doctor develops new technique to treat varicose veins 2Health News:UCLA doctor develops new technique to treat varicose veins 3Health News:Mediware's Transfusion Management Software Adopted by Four Additional Tenet Hospitals 2Health News:Mediware's Transfusion Management Software Adopted by Four Additional Tenet Hospitals 3
Colloidal Gold Conjugated, Goat anti-human IgM (Mu Chain) - 50 OD...
Colloidal Gold Conjugated, Goat anti-human IgA (Alpha Chain) - 50 OD...
Polyester ribbon impregnated with conjugated Protein A - .50 OD per sq. cm....
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Medicine Products: